Name: Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: HCIT3008
Price: 4350 USD
Availability: InStock

Chemotherapy Induced Peripheral Neuropathy Treatment Market 2023-2030

Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Chemotherapy-Induced Peripheral Neuropathy Treatment Market is segmented&nbsp;By Product (Calcium Channel &Aacute;2-delta Ligands, Antidepressants, Opioids, Others),&nbsp;By Application (Platinum Agents, Taxanes, Vinca Alkaloids, Others),&nbsp;By End-Users (Hospitals &amp; Clinics, Cancer Centers),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

&nbsp;

<blockquote>
Chemotherapy-Induced Peripheral Neuropathy Treatment Market was valued at USD&nbsp;million in 2021. It is forecasted to reach USD million by 2029, growing at a CAGR of 5 % during the forecast period (2023-2030).&nbsp;
</blockquote>

Chemotherapy-induced peripheral neuropathy is a serious clinical problem induced by several chemotherapeutics drugs or cytotoxic drugs such as platinum, taxanes, and vinca alkaloids eribulin, epothilones, and bortezomib. These drugs cause different pathological problems to the neurons. The pathological problems lead to the degeneration of peripheral sensory and motor nerves and cause patients to present with sensory disturbances, balance problems, or weakness. The technological advancement in the treatment and diagnosis of cancer and the rising incidence of chemotherapy-induced peripheral neuropathy is expected to propel the market growth. Moreover, the increasing demand for cost-efficient therapeutics in emerging regions is an opportunity for market growth.

As per DataM Intelligence, Chemotherapy-Induced Peripheral Neuropathy Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Chemotherapy-Induced Peripheral Neuropathy Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Chemotherapy-Induced Peripheral Neuropathy Treatment Market in the United States and Canada produces the utmost share. Whereas the European Chemotherapy-Induced Peripheral Neuropathy Treatment Market is projected to continue its presence globally during the period of 2023- 2030.

&nbsp;

<h3>Chemotherapy Induced Peripheral Neuropathy Treatment Market Scope</h3>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			CAGR
			</td>
			<td>
			5%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Product, By Application,&nbsp;By End-Users,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Regions Analyzed
			</td>
			<td>
			North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.
			</td>
		</tr>
		<tr>
			<td>
			Major Companies Covered
			</td>
			<td>
			Abbott Laboratories, EKF Diagnostics Holdings plc, BioM&eacute;rieux SA, Atlas Medical, Quidel Corporation, BIOSYNEX SA, Prestige Brands Holdings, Swiss Precision Diagnostics (SPD) GmbH, Piramal Enterprises, NG BIOTECH SAS, and among the major companies listed in the final report.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

To know more&nbsp;<a href="https://www.datamintelligence.com/download-sample/chemotherapy-induced-peripheral-neuropathy-treatment-market">Download Sample</a>

&nbsp;

<h3>Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics:</h3>

Continuous rise in R&amp;D will continue supporting the growth of the market during the forecast period. 

The companies operating in the chemotherapy-induced peripheral neuropathy market are constantly developing efficient drugs and medications to manage chemotherapy. Cancerous cells in the body make it critical to administer minor doses of drugs for peripheral neuropathy. Henceforth, the key market players in the global chemotherapy-induced peripheral neuropathy market are ramping up their oncological research investments. For instance, in December 2021, Paxman KTP created a new device to prevent chemotherapy side-effect CIPN. University of Huddersfield and Paxman partnered to develop a medical cooling system to prevent Chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes progressive and often irreversible pain or sensitivity in the hands and feet of patients undergoing chemotherapy leading to delays and discontinuation of treatment.

&nbsp;Also, collaboration with research institutes is driving the growth of the global market. Harvard Health Reviews have been offering relevant signals for the management and treatment of neuropathy. Numerous chemotherapy-induced peripheral neuropathy market companies are expected to collaborate with Harvard&#39;s research fraternity to reap the benefits of collaborative research. The Harvard Medical School insights have already helped numerous companies, research units, and chemotherapy-induced peripheral neuropathy&#39;stand nature and uropathy.

However, the adverse effect associated with the treatment may hamper the global chemotherapy-induced peripheral neuropathy treatment market.

<h3>Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation:</h3>

The antidepressants segment accounted for the highest share in global chemotherapy-induced peripheral neuropathy treatment market.

Antidepressant contributes the major share of the chemotherapy-induced peripheral neuropathy treatment market. It has a clinically meaningful effect on chemotherapy-induced peripheral neuropathy. Adjunct treatment options for chemotherapy-induced peripheral neuropathy include a topical analgesic, a tricyclic antidepressant, an anticonvulsant, or an SNRI. Therefore, realizing the potential benefits of chemotherapy-induced peripheral neuropathy as an antidepressant will drive market growth during the forecast period.

The chemotherapy-induced peripheral neuropathy treatment market has been classified into platinum agents, taxanes, vinca alkaloids, and others based on the application. The Platinum Agents segment held a significant market share in the global chemotherapy-induced peripheral neuropathy treatment market in the forecast period. The major application of platinum agents is the chemotherapy-induced peripheral neuropathy treatment market. Platinum agents (carboplatin, cisplatin, and oxaliplatin) are a class of chemotherapy agents with a wide range of activity against several solid tumors. Toxicity to the peripheral nervous system is the key dose-reducing toxicity of a few platinum drugs of clinical interest. Among the platinum compounds, cisplatin is considered the most neurotoxic, inducing mainly sensory neuropathy of the upper and lower extremities.

<h3>Chemotherapy Induced Peripheral Neuropathy Treatment Market&nbsp;Geographical Penetration:</h3>

North America dominated the global market throughout the forecast period. 

Based on geography, the study analyzes the chemotherapy-induced peripheral neuropathy treatment market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East &amp; Africa.&nbsp;

North America dominated the global chemotherapy-induced peripheral neuropathy treatment market and is expected to retain its position during the forecast period. The U.S. contributed over xx % to the North American chemotherapy-induced peripheral neuropathy treatment market in 2022. The increase in the incidence and prevalence rate of different cancer has led to a rise in demand for cancer drugs. This growth is due to chemotherapy in earlier cancer treatment stages compared to other therapy options such as immunological therapy drugs and targeted therapy drugs used in the late stage.

The Asia Pacific is estimated to grow considerably in the chemotherapy-induced peripheral neuropathy treatment market during the forecast period. This growth can be accredited to the rapidly developing healthcare infrastructure and rising awareness programs in this region. Further, growing medical tourism in developing countries such as India, China, Singapore, and Malaysia is also estimated to positively youth the global chemotherapy-induced peripheral neuropathy treatment market.&nbsp;

<h3>Chemotherapy Induced Peripheral Neuropathy Treatment Market&nbsp;Competitive Landscape:</h3>

The chemotherapy-induced peripheral neuropathy treatment market is highly competitive. The key chemotherapy-induced peripheral neuropathy treatment players contributing to the global market&#39;s growth market include Regency Pharmaceuticals, Nemus Bioscience Inc, PledPharma, Immune PharmaceIncnc., and DermaXon LLC. The major players are adopting new product launches and expansion strategies for global growth in the chemotherapy-induced peripheral neuropathy treatment market. In March 2022, Asahi Kasei Pharma announced that a drug administration study began for the first patient in the Japan-US international phase 1 study of ART-123 (generic name: thrombomodulin alfa; marketed as Recomodulin Injection in Japan) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). This study is performed jointly with Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary of Asahi Kasei Corp. In September 2021, Novaremed acquired Metys Pharmaceuticals to expand its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications. This acquisition aims to deliver effective and well-tolerated medications to patients while simultaneously addressing the urgent need for non-addictive treatments.

<h3>COVID-19 Impact On&nbsp;Chemotherapy Induced Peripheral Neuropathy Treatment Market</h3>

Negative impact on the global chemotherapy-induced peripheral neuropathy treatment market.

The outbreak of COVID-19 has certainly impacted the global chemotherapy-induced peripheral neuropathy treatment market, as the lockdown has compelled the diagnosis of new cancer cases, which in turn has derailed the adoption rate of chemotherapy-induced peripheral neuropathy treatment amidst the COVID-19 pandemic. Therefore, the chemotherapy-induced peripheral neuropathy treatment market is expected to foresee a considerable decline in 2020.

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>
		Research Methodology
		</li>
		<li>
		Research Objective and Scope of the Report
		</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>
		Market Snippet by Product
		</li>
		<li>
		Market Snippet by Application
		</li>
		<li>
		Market Snippet by End-Users
		</li>
		<li>
		Market Snippet by Region
		</li>
	</ol>
	</li>
	<li>
	Market Dynamics

	<ol>
		<li>
		Market Impacting Factors
		</li>
		<li>
		Drivers

		<ol>
			<li>
			Increasing incidence of cancer
			</li>
			<li>
			Rising awareness in emerging economies
			</li>
		</ol>
		</li>
		<li>
		Restraints:

		<ol>
			<li>
			Side-effects of treatment &nbsp;&nbsp;
			</li>
		</ol>
		</li>
		<li>
		Opportunity
		</li>
		<li>
		Impact Analysis
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>
		Porter&#39;s Five Forces Analysis
		</li>
		<li>
		Supply Chain Analysis
		</li>
		<li>
		Value Chain Analysis
		</li>
		<li>
		PEST Analysis
		</li>
		<li>
		Pricing Analysis
		</li>
		<li>
		Regulatory Analysis
		</li>
		<li>
		Reimbursement Analysis
		</li>
		<li>
		Unmet Needs
		</li>
		<li>
		Patent Trends
		</li>
	</ol>
	</li>
	<li>
	COVID-19 Analysis

	<ol>
		<li>
		Analysis of Covid-19 on the Market

		<ol>
			<li>
			Before COVID-19 Market Scenario
			</li>
			<li>
			Present COVID-19 Market Scenario
			</li>
			<li>
			After COVID-19 or Future Scenario
			</li>
		</ol>
		</li>
		<li>
		Pricing Dynamics Amid Covid-19
		</li>
		<li>
		Demand-Supply Spectrum
		</li>
		<li>
		Government Initiatives Related to the Market During Pandemic
		</li>
		<li>
		Manufacturers Strategic Initiatives
		</li>
		<li>
		Conclusion&nbsp;
		</li>
	</ol>
	</li>
	<li>
	<h3>By Product</h3>

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
		</li>
		<li>
		Market Attractiveness Index, By Product Segment

		<ol>
			<li>
			Calcium Channel &Aacute;2-delta Ligands*

			<ol>
				<li>
				Introduction
				</li>
				<li>
				Market Size Analysis, and Y-o-Y Growth Analysis (%)
				</li>
			</ol>
			</li>
			<li>
			Antidepressants
			</li>
			<li>
			Opioids
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By Application</h3>

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
		</li>
		<li>
		Market Attractiveness Index, By Application Segment

		<ol>
			<li>
			Platinum Agents*

			<ol>
				<li>
				Introduction
				</li>
				<li>
				Market Size Analysis, and Y-o-Y Growth Analysis (%)
				</li>
			</ol>
			</li>
			<li>
			Taxanes
			</li>
			<li>
			Vinca Alkaloids
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By End-Users</h3>

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment
		</li>
		<li>
		Market Attractiveness Index, By End-Users Segment

		<ol>
			<li>
			Hospitals &amp; Clinics*

			<ol>
				<li>
				Introduction
				</li>
				<li>
				Market Size Analysis, and Y-o-Y Growth Analysis (%)
				</li>
			</ol>
			</li>
			<li>
			Cancer Centers
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
		</li>
		<li>
		Market Attractiveness Index, By Region
		</li>
		<li>
		North America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				The U.S.
				</li>
				<li>
				Canada
				</li>
				<li>
				Mexico
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Europe

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Germany
				</li>
				<li>
				The U.K.
				</li>
				<li>
				France
				</li>
				<li>
				Italy
				</li>
				<li>
				Spain
				</li>
				<li>
				Rest of Europe
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		South America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Brazil
				</li>
				<li>
				Argentina
				</li>
				<li>
				Rest of South America
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Asia Pacific

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				China
				</li>
				<li>
				India
				</li>
				<li>
				Japan
				</li>
				<li>
				Australia
				</li>
				<li>
				Rest of Asia Pacific
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		The Middle East and Africa

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Competitive Landscape

	<ol>
		<li>
		Competitive Scenario
		</li>
		<li>
		Market Positioning/Share Analysis
		</li>
		<li>
		Mergers and Acquisitions Analysis
		</li>
	</ol>
	</li>
	<li>
	<h3>Company Profiles</h3>

	<ol>
		<li>
		Asahi Kasei Pharma Corp*

		<ol>
			<li>
			Company Overview
			</li>
			<li>
			Product Portfolio and Description
			</li>
			<li>
			Key Highlights
			</li>
			<li>
			Financial Overview
			</li>
		</ol>
		</li>
		<li>
		Regency Pharmaceuticals
		</li>
		<li>
		MAKScientific LLC
		</li>
		<li>
		Metys Pharmaceuticals AG
		</li>
		<li>
		Nemus Bioscience Inc
		</li>
		<li>
		PledPharma
		</li>
		<li>
		Sova Pharmaceuticals Inc
		</li>
		<li>
		DermaXon LLC
		</li>
		<li>
		Immune Pharmaceuticals Inc.
		</li>
		<li>
		Solasia Pharma K.K.
		</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence</h3>

	<ol>
		<li>
		Appendix
		</li>
		<li>
		About Us and Services
		</li>
		<li>
		Contact Us
		</li>
	</ol>
	</li>
</ol>

&nbsp;

<h3>List of Tables</h3>

<h3> 
Table 1 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Product, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 2 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Application, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 3 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By End-Users, 2021, 2025 &amp; 2029 (US$ Million) 
Table 4 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Region, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 5 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Product, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 6 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Application, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 7 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By End-Users, 2021, 2025 &amp; 2029 (US$ Million) 
Table 8 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Country, 2022-2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 9 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Product, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 10 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Application, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 11 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By End-Users, 2021, 2025 &amp; 2029 (US$ Million) 
Table 12 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Country, 2022-2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 13 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Product, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 14 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Application, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 15 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By End-Users, 2021, 2025 &amp; 2029 (US$ Million) 
Table 16 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Country, 2022-2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 17 Asia Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Product, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 18 Asia Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Application, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 19 Asia Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By End-Users, 2021, 2025 &amp; 2029 (US$ Million) 
Table 20 Asia Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Country, 2021, 2025 &amp; 2029 (US$ Million) 
Table 21 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Product, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 22 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Application, 2021, 2025 &amp; 2029 (US$ Million)&nbsp;&nbsp; &nbsp; 
Table 23&nbsp; 
Table 24 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By End-Users, 2021, 2025 &amp; 2029 (US$ Million) 
Table 25 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, By Country, 2021, 2025 &amp; 2029 (US$ Million) 
Table 26 Asahi Kasei Pharma Corp: Overview&nbsp;&nbsp; &nbsp; 
Table 27 Asahi Kasei Pharma Corp: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 28 Asahi Kasei Pharma Corp: Key Developments&nbsp;&nbsp; &nbsp; 
Table 29 Regency Pharmaceuticals: Overview&nbsp;&nbsp; &nbsp; 
Table 30 Regency Pharmaceuticals: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 31 Regency Pharmaceuticals: Key Developments&nbsp;&nbsp; &nbsp; 
Table 32 MAKScientific LLC: Overview&nbsp;&nbsp; &nbsp; 
Table 33 MAKScientific LLC: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 34 MAKScientific LLC: Key Developments&nbsp;&nbsp; &nbsp; 
Table 35 Metys Pharmaceuticals AG: Overview&nbsp;&nbsp; &nbsp; 
Table 36 Metys Pharmaceuticals AG: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 37 Metys Pharmaceuticals AG: Key Developments&nbsp;&nbsp; &nbsp; 
Table 38 Nemus Bioscience Inc: Overview&nbsp;&nbsp; &nbsp; 
Table 39 Nemus Bioscience Inc: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 40 Nemus Bioscience Inc: Key Developments&nbsp;&nbsp; &nbsp; 
Table 41 PledPharma: Overview&nbsp;&nbsp; &nbsp; 
Table 42 PledPharma: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 43 PledPharma: Key Developments&nbsp;&nbsp; &nbsp; 
Table 44 Sova Pharmaceuticals Inc: Overview&nbsp;&nbsp; &nbsp; 
Table 45 Sova Pharmaceuticals Inc: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 46 Sova Pharmaceuticals Inc: Key Developments&nbsp;&nbsp; &nbsp; 
Table 47 DermaXon LLC: Overview&nbsp;&nbsp; &nbsp; 
Table 48 DermaXon LLC: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 49 DermaXon LLC: Key Developments&nbsp;&nbsp; &nbsp; 
Table 50 Immune Pharmaceuticals Inc.: Overview&nbsp;&nbsp; &nbsp; 
Table 51 Immune Pharmaceuticals Inc.: Product Portfolio&nbsp;&nbsp; &nbsp; 
Table 52 Immune Pharmaceuticals Inc.: Key Developments&nbsp;&nbsp; &nbsp; 
Table 53 Solasia Pharma K.K.: Overview&nbsp;&nbsp; &nbsp; 
Table 54 Solasia Pharma K.K.: Product Portfolio 
Table 55 Solasia Pharma K.K.: Key Developments</h3>

<h3>List of Figures 
Figure 1 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Product, 2021 &amp; 2029 (%) 
Figure 2 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Application, 2021 &amp; 2029 (%) 
Figure 3 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By End-Users, 2021 &amp; 2029 (%) 
Figure 4 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Region, 2021 &amp; 2029 (%) 
Figure 5 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 6 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Y-o-Y Growth, By Product, 2021-2029 (%) 
Figure 7 Calcium Channel &Aacute;2-delta Ligands: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 8 Antidepressants: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 9 Opioids: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 10 Others: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 11 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Y-o-Y Growth, By Application, 2021-2029 (%) 
Figure 12 Platinum Agents: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 13 Taxanes: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 14 Vinca Alkaloids: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 15 Others: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 16 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Y-o-Y Growth, By End-Users, 2021-2029 (%) 
Figure 17 Hospitals &amp; Clinics: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 18 Cancer Centers: Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 19 Global Chemotherapy-Induced Peripheral Neuropathy Treatment Market Y-o-Y Growth, By Region, 2021-2029 (%) 
Figure 20 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 21 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Product, 2021 &amp; 2029 (%) 
Figure 22 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Application, 2021 &amp; 2029 (%) 
Figure 23 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Type, 2021 &amp; 2029 (%) 
Figure 24 North America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 25 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 26 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Product, 2021 &amp; 2029 (%) 
Figure 27 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Application, 2021 &amp; 2029 (%) 
Figure 28 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By End-Users, 2021 &amp; 2029 (%) 
Figure 29 South America Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 30 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 31 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Product, 2021 &amp; 2029 (%) 
Figure 32 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Application, 2021 &amp; 2029 (%) 
Figure 33 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By End-Users, 2021 &amp; 2029 (%) 
Figure 34 Europe Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 35 Asia-Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 36 Asia-Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Product, 2021 &amp; 2029 (%) 
Figure 37 Asia-Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Application, 2021 &amp; 2029 (%) 
Figure 38 Asia-Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By End-Users, 2021 &amp; 2029 (%) 
Figure 39 Asia-Pacific Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 40 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Value, 2022-2029 (US$ Million) 
Figure 41 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Product, 2021 &amp; 2029 (%) 
Figure 42 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Application, 2021 &amp; 2029 (%) 
Figure 43 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By End-Users, 2021 &amp; 2029 (%) 
Figure 44 The Middle East &amp; Africa Chemotherapy-Induced Peripheral Neuropathy Treatment Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 45 Asahi Kasei Pharma Corp: Financials 
Figure 46 Regency Pharmaceuticals: Financials 
Figure 47 MAKScientific LLC: Financials 
Figure 48 Metys Pharmaceuticals AG: Financials 
Figure 49 Nemus Bioscience Inc: Financials 
Figure 50 PledPharma: Financials 
Figure 51 Sova Pharmaceuticals Inc: Financials 
Figure 52 DermaXon LLC: Financials 
Figure 53 Immune Pharmaceuticals Inc.: Financials 
Figure 54 Solasia Pharma K.K.: Financials 
&nbsp;</h3>